

# Q2 2025 *Results*



- We delivered double-digit sales growth in Q2. Our strategic focus on innovation continues to drive our top line performance, with significant contributions from our nine newly launched medicines and vaccines. With important pipeline milestones anticipated in H2, we look forward to bringing more scientific breakthroughs to patients. •

*Paul Hudson*

Chief Executive Officer, Sanofi

---

## *Q2 2025 Company Sales*

**€10.0bn**

+10.1% at constant exchange rates  
+6.0% on a reported basis

## *Q2 2025 Business Earnings Per Share*

**€1.59**

+8.3% at constant exchange rates  
+1.9% on a reported basis

---

## *Sales by Category*



Dupixent

**€3.8bn**



Pharma launches

**€0.9bn**



Vaccines

**€1.2bn**



Other medicines

**€4.2bn**

**sanofi**

# Q2 2025 *Results*

## *Sales by Geography*

US  
**€4.9bn**

Europe  
**€2.1bn**

Rest of the World  
**€3.0bn**

---



## *Strong Pipeline Progress*

- **3** regulatory approvals in dermatology, oncology and vaccines.
- **3** phase 3 readouts in COPD and rabies prevention.
- **7** regulatory designations, including orphan and fast track, in rare diseases, neurology, and oncology.



## *Sustainability*

Sanofi ranked the world's 10th most sustainable company and **number 1 in Pharma & Biotech**, by TIME.

---

For further information on Q2 2025 results and definitions of financial indicators, please refer to the press release issued on July 31, 2025 at: [www.sanofi.com/en/investors](https://www.sanofi.com/en/investors)